










































Pharmaceuticals – Pipeline Overview¹ (as of Feb 15, 2023)

Phase 0 ²	Phase I	Phase II	Phase III
DGKalpha Inh (BAY 2862789)  ●	Elimusertib (ATR Inhibitor) (BAY 1895344)  ●	Regorafenib (combi Nivolumab) (BAY 734506)  ○	Copanlisib (PI3K Inhibitor)  ○ // Non-Hodgkin Lymphoma (CHRONOS-4)
PSMA TAC (BAY 3546828)  ●	AhR Inhibitor (BAY 2416964)  ●	Asundexian (FXIa Inhibitor) (BAY 2433334)  ●	Darolutamide (AR Inhibitor)  ○ // Prostate Cancer (mHSPC) (ARANOTE) // Adjuvant Prostate Cancer (DASL-HiCaP)
PSMA SMOL TAC (BAY 3563254)  ●	mEGFR Inhibitor (BAY 2927088)  ●	Runcaciguat (sGC Activator) (BAY 1101042)  ●	Finerenone (MR Antagonist)  ○ // Heart Failure (HFmr/pEF) (FINEARTS-HF) // Non-diabetic CKD (FIND-CKD)
VVD NRF2 Inh (BAY 3605349)  ●	DGKzeta Inhibitor (BAY 2965501)  ●	BDKRB1 Receptor Antagonist (BAY 2395840)  ●	Vericiguat (sGC Stimulator)  ○ // Heart Failure (HFREF) (VICTOR ³)
VVD STAT3 Inh (BAY 3630914)  ●	CCR8 Ab (BAY 3375968)  ●	Gadoquatrane (High Relaxivity Contrast Agent) (BAY 1747846)  ●	Asundexian (FXIa Inhibitor)  ● // Stroke Prevention in Atrial Fibrillation (OCEANIC-AF) // 2 ^o Stroke Prevention (OCEANIC-STROKE)
SEMA 3a (BAY 3401016)  ●	Congestive Heart Failure Gene Therapy (AB-1002 formerly NAN-101)  ●	Adrenomedullin Pegol (PEG-ADM) (BAY 1097761)  ●	Elinzanetant (Neurokinin-1,3 Rec Antagonist)  ● // Vasomotor Symptoms (OASIS)
LGMD2i Gene Therapy (LION-101)  ●	sGC Activator (BAY 3283142)  ●	Zabedoserib (IRAK4 Inh.) (BAY 1834845)  ●	
Next Generation Liver MRI (BAY 3393081)  ●	Anti-a2AP (BAY 3018250)  ●		
	P2X4 Antagonist (BAY 2328065)  ●		
	BDKRB1 Receptor Antagonist (BAY 2395840)  ●		
	sGC Activator (BAY 1211163)  ●		
	Bemdaneprocel (Parkinson's Disease Cell Therapy) (BRT-DA01)  ●		
	Parkinson's Disease Gene Therapy (AB-1005 formerly AAV2-GDNF-PD)  ●		
	Multiple System Atrophy Gene Therapy (AB-1005 formerly AAV2-GDNF-MSA)  ●		
	Pompe Disease Gene Therapy (ACTUS-101)  ●		
	Huntington's Disease Gene Therapy (BV-101)  ●		
	GPR84 Antagonist (BAY 3178275)  ●		

Submissions
Darolutamide (AR Inhibitor) / ADT with Chemotherapy  ○ // EU, Japan, China: mHSPC
Aflibercept 8MG  ○ // EU, US ³ : Diabetic Macular Edema (DME) // EU, US ² : Neovasc. Age-rel. Macular Degen. (nAMD)

- Oncology
- Cardiovascular Diseases
- Women's Health
- Others

- New molecular entity
- Life cycle management

-  Antibody
-  Biologic
-  Cell Therapy
-  Contrast Agent
-  Gene Therapy
-  Radiotherapy
-  Small Molecule

¹ Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit ² Pre-clinical selected assets on path to IND ³ Conducted by Merck & Co ⁴ US submission made by Regeneron